NO20082514L - Aminopyrimidiner anvendelige som kinaseinhibitorer - Google Patents

Aminopyrimidiner anvendelige som kinaseinhibitorer

Info

Publication number: NO20082514L
Authority: NO; Norway
Prior art keywords: kinase inhibitors; aminopyrimidines useful; aminopyrimidines; useful; kinase
Prior art date: 2005-11-03

Application number

NO20082514A

Other languages

English (en)

Inventor

Michael Paul Mortimore

Damien Fraysse

Daniel Robinson

Andrew Miller

Hayley Binch

Simon Everitt

Chris Davis

Michael O'donnell

Joanne Pinder

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-03

Filing date

2008-05-30

Publication date

2008-07-18

2008-05-30 Application filed by Vertex Pharma filed Critical Vertex Pharma

2008-07-18 Publication of NO20082514L publication Critical patent/NO20082514L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Immunology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Lubricants (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20082514A 2005-11-03 2008-05-30 Aminopyrimidiner anvendelige som kinaseinhibitorer NO20082514L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US73295105P	2005-11-03	2005-11-03
US73355705P	2005-11-04	2005-11-04
PCT/US2006/042994 WO2007056164A2 (en)	2005-11-03	2006-11-03	Aminopyrimidines useful as kinase inhibitors

Publications (1)

Publication Number	Publication Date
NO20082514L true NO20082514L (no)	2008-07-18

Family

ID=38023840

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO20082508A NO20082508L (no)	2005-11-03	2008-05-30	Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20082514A NO20082514L (no)	2005-11-03	2008-05-30	Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20082517A NO20082517L (no)	2005-11-03	2008-05-30	Aminopyrimidiner anvendelige som kinaseinhibitorer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO20082508A NO20082508L (no)	2005-11-03	2008-05-30	Aminopyrimidiner anvendelige som kinaseinhibitorer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20082517A NO20082517L (no)	2005-11-03	2008-05-30	Aminopyrimidiner anvendelige som kinaseinhibitorer

Country Status (18)

Country	Link
US (7)	US7820685B2 (no)
EP (3)	EP1954277B1 (no)
JP (5)	JP5249770B2 (no)
KR (3)	KR20080067694A (no)
CN (3)	CN101316597B (no)
AR (3)	AR056763A1 (no)
AU (3)	AU2006311797A1 (no)
BR (3)	BRPI0619706A2 (no)
CA (3)	CA2627808A1 (no)
ES (2)	ES2533241T3 (no)
IL (3)	IL191043A0 (no)
MX (3)	MX2008005818A (no)
NO (3)	NO20082508L (no)
NZ (4)	NZ594383A (no)
RU (5)	RU2423361C2 (no)
SG (2)	SG166828A1 (no)
TW (3)	TW200736250A (no)
WO (3)	WO2007056164A2 (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6660731B2 (en)	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
PT1317448E (pt)	2000-09-15	2005-08-31	Vertex Pharma	Compostos de pirazole uteis como inibidores de proteina-quinase
SE0104140D0 (sv) *	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
US7601718B2 (en)	2003-02-06	2009-10-13	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of protein kinases
AU2006215386B2 (en) *	2005-02-16	2009-06-11	Astrazeneca Ab	Chemical compounds
CA2608009A1 (en) *	2005-05-16	2006-11-23	Astrazeneca Ab	Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
NZ595182A (en) *	2005-10-18	2012-12-21	Janssen Pharmaceutica Nv	Pharmaceutical uses of 4-cyano-1H-imidazole-2-carboxylic acid { 2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl} -amide
US20080287475A1 (en) *	2005-10-28	2008-11-20	Astrazeneca Ab	4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer
EP1954277B1 (en)	2005-11-03	2017-01-18	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
CA2629781A1 (en) *	2005-11-16	2007-05-24	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
US8697716B2 (en)	2006-04-20	2014-04-15	Janssen Pharmaceutica Nv	Method of inhibiting C-KIT kinase
ES2566772T3 (es)	2006-04-20	2016-04-15	Janssen Pharmaceutica, N.V.	Inhibidores de la quinasa c-fms
NZ576750A (en)	2006-11-02	2012-01-12	Vertex Pharma	Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
CA2673353A1 (en)	2006-12-19	2008-06-26	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as inhibitors of protein kinases
CN101663295B (zh)	2007-03-09	2014-11-05	沃泰克斯药物股份有限公司	可用作蛋白激酶抑制剂的氨基嘧啶类化合物
ES2374335T3 (es) *	2007-03-09	2012-02-15	Vertex Pharmaceuticals Incorporated	Aminopirimidinas útiles como inhibidores de proteína quinasas.
CA2679701A1 (en)	2007-03-09	2008-09-18	Vertex Pharmaceuticals Incorporated	Aminopyridines useful as inhibitors of protein kinases
WO2008128009A2 (en)	2007-04-13	2008-10-23	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
CN101679429A (zh) *	2007-04-18	2010-03-24	阿斯利康(瑞典)有限公司	5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途
EP2152696B1 (en)	2007-05-02	2014-09-24	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
JP5389785B2 (ja) *	2007-05-02	2014-01-15	バーテックスファーマシューティカルズインコーポレイテッド	キナーゼ阻害剤として有用なチアゾールおよびピラゾール
WO2008137622A2 (en) *	2007-05-02	2008-11-13	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
US20100137398A1 (en) *	2007-05-04	2010-06-03	Novartis Ag	Use of hdac inhibitors for the treatment of gastrointestinal cancers
UA99459C2 (en) *	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
CA2687966A1 (en) *	2007-05-24	2008-12-04	Vertex Pharmaceuticals Incorporated	Thiazoles and pyrazoles useful as kinase inhibitors
JP2010529193A (ja) *	2007-06-11	2010-08-26	ミイカナセラピューティクスインコーポレイテッド	置換ピラゾール化合物
WO2009018415A1 (en) *	2007-07-31	2009-02-05	Vertex Pharmaceuticals Incorporated	Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
CA2695753A1 (en) *	2007-08-15	2009-02-19	Vertex Pharmaceuticals Incorporated	Compounds useful as protein kinases inhibitors
MX2010002772A (es)	2007-09-21	2010-03-31	Array Biopharma Inc	Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucocinasa para el tratamiento de diabetes mellitus.
WO2009086012A1 (en) *	2007-12-20	2009-07-09	Curis, Inc.	Aurora inhibitors containing a zinc binding moiety
US20110033461A1 (en) *	2008-03-12	2011-02-10	Vladimir Ratushny	Combination Therapy for the Treatment of Cancer
US8324199B2 (en) *	2008-03-13	2012-12-04	Bristol-Myers Squibb Company	Pyridazine derivatives as factor xia inhibitors
SG10201808863UA (en) *	2008-03-17	2018-11-29	Scripps Research Inst	Combined chemical and genetic approaches for generation of induced pluripotent stem cells
CN102119157A (zh) *	2008-06-11	2011-07-06	阿斯利康(瑞典)有限公司	用于治疗癌症和骨髓增生性疾病的三环2，4-二氨基-l，3，5-三嗪衍生物
EP2352827A4 (en) *	2008-09-05	2016-07-20	Celgene Avilomics Res Inc	ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS
MX2011003447A (es) *	2008-09-30	2011-07-29	Astrazeneca Ab	Inhibidores heterociclicos de jak quinasa.
MX2011006725A (es)	2008-12-22	2011-09-15	Millennium Pharm Inc	Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
US20120202818A1 (en) *	2009-06-09	2012-08-09	California Capital Equity, Llc	Ureidophenyl substituted triazine derivatives and their therapeutical applications
SG179172A1 (en)	2009-09-16	2012-04-27	Avila Therapeutics Inc	Protein kinase conjugates and inhibitors
RU2012132473A (ru)	2009-12-30	2014-02-10	Селджин Авиломикс,Инк	Лиганд-направленная ковалентная модификация белка
CA2803446C (en)	2010-07-02	2019-06-04	University Health Network	Use of plk4 antagonists for treating pten mutant diseases
SG10201505951VA (en) *	2010-07-30	2015-08-28	Oncotherapy Science Inc	Quinoline derivatives and melk inhibitors containing the same
WO2012112674A2 (en)	2011-02-15	2012-08-23	The Johns Hopkins University	Compounds and methods of use thereof for treating neurodegenerative disorders
PT3686193T (pt)	2011-07-27	2022-05-20	Astrazeneca Ab	Compostos de 2-(2,4,5-anilino-substituídos)pirimidina
US8637537B2 (en)	2011-08-25	2014-01-28	Genentech, Inc.	Serine/threonine kinase inhibitors
US9221798B2 (en) *	2011-09-05	2015-12-29	Zhejian Hisun Pharmaceutical Co., Ltd.	4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine derivatives having activity of inhibiting protein kinase and use thereof
CN107898790B (zh)	2011-11-30	2024-06-21	埃默里大学	用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
RU2014129740A (ru)	2011-12-22	2016-02-10	Ф.Хоффманн-Ля Рош Аг	Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы
AR092809A1 (es)	2012-03-16	2015-05-06	Axikin Pharmaceuticals Inc	3,5-diaminopirazol como inhibidor de quinasa
ES2860299T3 (es)	2012-04-24	2021-10-04	Vertex Pharma	Inhibidores de DNA-PK
US20130310340A1 (en)	2012-05-16	2013-11-21	Rigel Pharmaceuticals, Inc.	Method of treating muscular degradation
WO2013177367A2 (en)	2012-05-23	2013-11-28	The Johns Hopkins University	Compounds and methods of use thereof for treating neurodegenerative disorders
SG10201805807PA (en)	2012-06-26	2018-08-30	Del Mar Pharmaceuticals	Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
BR112015010109A2 (pt) *	2012-11-05	2017-07-11	Nant Holdings Ip Llc	derivados de indol-5-ol substituídos e suas aplicações terapêuticas
BR112015021888B1 (pt)	2013-03-12	2022-08-09	Vertex Pharmaceuticals Incorporated	Inibidores de dna-pk, seus usos e composição farmacêutica
RU2015143657A (ru) *	2013-03-15	2017-04-27	Нэнтбайосайенс, Инк.	Замещенные производные индол-5-ола и их терапевтические применения
WO2014168986A1 (en)	2013-04-08	2014-10-16	Brown Dennis M	Therapeutic benefit of suboptimally administered chemical compounds
WO2014190207A1 (en) *	2013-05-22	2014-11-27	The Regents Of The University Of California	Aurora kinase inhibitors
NZ631142A (en)	2013-09-18	2016-03-31	Axikin Pharmaceuticals Inc	Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
PL3057953T3 (pl)	2013-10-17	2019-01-31	Vertex Pharmaceuticals Incorporated	Kokryształy (S)-N-metylo-8-(1-((2'-metylo-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK
JP6525474B2 (ja)	2013-12-06	2019-06-05	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
AR103264A1 (es)	2014-12-23	2017-04-26	Axikin Pharmaceuticals Inc	Derivados de 3,5-aminopirazol como inhibidores de quinasa rc
EP3302465A1 (en)	2015-06-05	2018-04-11	Vertex Pharmaceuticals Incorporated	Triazoles for the treatment of demyelinating diseases
US20180207173A1 (en)	2015-07-21	2018-07-26	Millennium Pharmaceuticals, Inc.	Administration of aurora kinase inhibitor and chemotherapeutic agents
US10722484B2 (en)	2016-03-09	2020-07-28	K-Gen, Inc.	Methods of cancer treatment
KR20190062485A (ko)	2016-09-27	2019-06-05	버텍스 파마슈티칼스 인코포레이티드	Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
RU2757218C2 (ru) *	2016-12-14	2021-10-12	Интервет Интернэшнл Б.В.	Аминопиразолы в качестве селективных ингибиторов янус-киназы
BR112019013593A2 (pt)	2016-12-28	2020-01-07	Minoryx Therapeutics S.L.	Compostos de isoquinolina, métodos para sua preparação, e usos terapêuticos dos mesmos em afecções associadas à alteração da atividade de beta galactosidase
CN106841420A (zh) *	2016-12-30	2017-06-13	广州中大南沙科技创新产业园有限公司	一种LC‑MS/MS测定大鼠血浆中Ly‑7u浓度的方法
WO2019195658A1 (en)	2018-04-05	2019-10-10	Dana-Farber Cancer Institute, Inc.	Sting levels as a biomarker for cancer immunotherapy
CN110132795A (zh) *	2019-05-20	2019-08-16	华核（天津）新技术开发有限公司	放射性去污效率测试方法
WO2021041532A1 (en)	2019-08-26	2021-03-04	Dana-Farber Cancer Institute, Inc.	Use of heparin to promote type 1 interferon signaling
WO2021178485A1 (en) *	2020-03-06	2021-09-10	National Health Research Institutes	Pyrimidine compounds and their pharmaceutical uses
WO2021222637A1 (en)	2020-04-30	2021-11-04	United States Government As Represented By The Department Of Veterans Affairs	Krüppel-like factor 15 (klf15) small molecule agonists in kidney disease
US12084453B2 (en)	2021-12-10	2024-09-10	Incyte Corporation	Bicyclic amines as CDK12 inhibitors

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3133081A (en)		1964-05-12		J-aminoindazole derivatives
US3935183A (en) *	1970-01-26	1976-01-27	Imperial Chemical Industries Limited	Indazole-azo phenyl compounds
BE754242A (fr) *	1970-07-15	1971-02-01	Geigy Ag J R	Diamino-s-triazines et dinitro-s-triazines
US3998951A (en)	1974-03-13	1976-12-21	Fmc Corporation	Substituted 2-arylquinazolines as fungicides
DE2458965C3 (de) *	1974-12-13	1979-10-11	Bayer Ag, 5090 Leverkusen	3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
MA18829A1 (fr)	1979-05-18	1980-12-31	Ciba Geigy Ag	Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
DOP1981004033A (es)	1980-12-23	1990-12-29	Ciba Geigy Ag	Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
SE8102193L (sv)	1981-04-06	1982-10-07	Pharmacia Ab	Terapeutiskt aktiv organisk forening och dess anvendning
SE8102194L (sv)	1981-04-06	1982-10-07	Pharmacia Ab	Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
JPS58124773A (ja) *	1982-01-20	1983-07-25	Mitsui Toatsu Chem Inc	５−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤
EP0136976A3 (de)	1983-08-23	1985-05-15	Ciba-Geigy Ag	Verwendung von Phenylpyrimidinen als Pflanzenregulatoren
DE3725638A1 (de)	1987-08-03	1989-02-16	Bayer Ag	Neue aryloxy (bzw. thio)aminopyrimidine
US5710158A (en) *	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5597920A (en)	1992-04-30	1997-01-28	Neurogen Corporation	Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes
JPH0665237A (ja)	1992-05-07	1994-03-08	Nissan Chem Ind Ltd	置換ピラゾール誘導体および農園芸用殺菌剤
JP3588116B2 (ja)	1993-10-01	2004-11-10	ノバルティスアクチェンゲゼルシャフト	薬理活性のピリミジンアミン誘導体およびその製造方法
JPH10509708A (ja)	1994-11-10	1998-09-22	コアセラピューティクス，インコーポレイティド	プロテイン・キナーゼのインヒビターとして有用な医薬ピラゾール組成物
IL117659A (en)	1995-04-13	2000-12-06	Dainippon Pharmaceutical Co	Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
US5935966A (en)	1995-09-01	1999-08-10	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
CA2230896A1 (en)	1995-09-01	1997-03-13	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en)	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
US6716575B2 (en)	1995-12-18	2004-04-06	Sugen, Inc.	Diagnosis and treatment of AUR1 and/or AUR2 related disorders
ID19609A (id)	1996-07-13	1998-07-23	Glaxo Group Ltd	Senyawa-senyawa heterosiklik
JPH10130150A (ja)	1996-09-05	1998-05-19	Dainippon Pharmaceut Co Ltd	酢酸アミド誘導体からなる医薬
GB9619284D0 (en)	1996-09-16	1996-10-30	Celltech Therapeutics Ltd	Chemical compounds
JP4205168B2 (ja)	1996-10-02	2009-01-07	ノバルティスアクチエンゲゼルシヤフト	ピリミジン誘導体およびその製造法
BR9712530A (pt)	1996-10-11	1999-10-19	Warner Lambert Co	Inibidores de ésteres de asparato de enzima de conversão de interleucina-1beta
AU741203B2 (en)	1997-10-10	2001-11-22	Cytovia, Inc.	Dipeptide apoptosis inhibitors and the use thereof
US6267952B1 (en)	1998-01-09	2001-07-31	Geltex Pharmaceuticals, Inc.	Lipase inhibiting polymers
JP2000026421A (ja)	1998-01-29	2000-01-25	Kumiai Chem Ind Co Ltd	ジアリ―ルスルフィド誘導体及び有害生物防除剤
CA2321153A1 (en)	1998-02-17	1999-08-19	Timothy D. Cushing	Anti-viral pyrimidine derivatives
CN1297354A (zh)	1998-03-16	2001-05-30	西托维亚公司	二肽卡斯帕酶抑制剂及其用途
PL204628B1 (pl)	1998-06-02	2010-01-29	Osi Pharmaceuticals	Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne
US6489344B1 (en)	1998-06-19	2002-12-03	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
AU5777299A (en) *	1998-08-21	2000-03-14	Du Pont Pharmaceuticals Company	Isoxazolo(4,5-d)pyrimidines as CRF antagonists
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
ATE294796T1 (de)	1998-10-08	2005-05-15	Astrazeneca Ab	Chinazolin derivate
GB9828640D0 (en)	1998-12-23	1999-02-17	Smithkline Beecham Plc	Novel method and compounds
GB9828511D0 (en)	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
DE60012721D1 (de)	1999-03-29	2004-09-09	Uutech Ltd	Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
GB9914258D0 (en) *	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
US20020065270A1 (en)	1999-12-28	2002-05-30	Moriarty Kevin Joseph	N-heterocyclic inhibitors of TNF-alpha expression
IL145757A (en) *	2000-02-05	2007-12-03	Vertex Pharma	History of pyrazole and pharmaceutical preparations containing them
KR20030024659A (ko)	2000-02-17	2003-03-26	암겐 인코포레이티드	키나제 억제제
GB0004887D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
JP4806154B2 (ja)	2000-04-03	2011-11-02	バーテックスファーマシューティカルズインコーポレイテッド	セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
EP1299381B1 (en) *	2000-06-28	2008-05-07	AstraZeneca AB	Substituted quinazoline derivatives and their use as inhibitors
KR100904788B1 (ko)	2000-07-21	2009-06-25	쉐링 코포레이션	Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드
JP2004507526A (ja)	2000-08-31	2004-03-11	ファイザー・プロダクツ・インク	ピラゾール誘導体及びそのプロテインキナーゼ阻害剤としての使用
ZA200301696B (en)	2000-09-15	2004-04-28	Vertex Pharma	Isoxazoles and their use as inhibitors of erk.
PT1317448E (pt)	2000-09-15	2005-08-31	Vertex Pharma	Compostos de pirazole uteis como inibidores de proteina-quinase
US6610677B2 (en)	2000-09-15	2003-08-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) *	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en)	2000-09-15	2009-01-06	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) *	2000-09-15	2003-09-02	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6641579B1 (en) *	2000-09-29	2003-11-04	Spectrasonics Imaging, Inc.	Apparatus and method for ablating cardiac tissue
DE10061863A1 (de)	2000-12-12	2002-06-13	Basf Ag	Verfahren zur Herstellung von Triethylendiamin (TEDA)
US6716851B2 (en) *	2000-12-12	2004-04-06	Cytovia, Inc.	Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
CN100408573C (zh) *	2000-12-21	2008-08-06	沃泰克斯药物股份有限公司	可用作蛋白激酶抑制剂的吡唑化合物
MY130778A (en)	2001-02-09	2007-07-31	Vertex Pharma	Heterocyclic inhibitiors of erk2 and uses thereof
US6759983B2 (en) *	2001-03-28	2004-07-06	Strategic Analysis, Inc.	Method and device for precise geolocation of low-power, broadband, amplitude-modulated signals
US6949544B2 (en)	2001-03-29	2005-09-27	Vertex Pharmaceuticals Incorporated	Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
CA2443487A1 (en)	2001-04-13	2002-10-24	Vertex Pharmaceuticals Incorporated	Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1383771A1 (en)	2001-04-20	2004-01-28	Vertex Pharmaceuticals Incorporated	9-deazaguanine derivatives as inhibitors of gsk-3
CA2446864C (en)	2001-05-16	2011-02-15	Vertex Pharmaceuticals Incorporated	Inhibitors of src and other protein kinases
MXPA03011652A (es)	2001-06-15	2004-05-31	Vertex Pharma	5-(2-aminopirimidin-4-il) benzioxazoles como inhibidores de proteinas cinasa.
ES2271283T3 (es)	2001-07-03	2007-04-16	Vertex Pharmaceuticals Incorporated	Isoxazolil-pirimidinas como inhibidores de las proteinas quinasas src y lck.
US6698980B2 (en) *	2001-07-30	2004-03-02	Stewart Mining Products Inc.	Rock stabilizing apparatus and method
WO2003026665A1 (en)	2001-09-26	2003-04-03	Bayer Pharmaceuticals Corporation	2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
US6569499B2 (en) *	2001-10-02	2003-05-27	Xerox Corporation	Apparatus and method for coating photoreceptor substrates
ATE466581T1 (de)	2001-12-07	2010-05-15	Vertex Pharma	Verbindungen auf pyrimidin-basis als gsk-3-hemmer
EP1485100B1 (en)	2002-03-15	2010-05-05	Vertex Pharmaceuticals Incorporated	Azinylaminoazoles as inhibitors of protein kinases
WO2003078427A1 (en) *	2002-03-15	2003-09-25	Vertex Pharmaceuticals, Inc.	Azolylaminoazines as inhibitors of protein kinases
US7863282B2 (en) *	2003-03-14	2011-01-04	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of protein kinases
AU2003220300A1 (en) *	2002-03-15	2003-09-29	Binch, Hayley	Compositions useful as inhibitors of protein kinases
WO2003078426A1 (en)	2002-03-15	2003-09-25	Vertex Pharmaceuticals, Inc.	Azolylaminoazine as inhibitors of protein kinases
US20030207873A1 (en)	2002-04-10	2003-11-06	Edmund Harrington	Inhibitors of Src and other protein kinases
AU2003237121A1 (en)	2002-04-26	2003-11-10	Vertex Pharmaceuticals Incorporated	Pyrrole derivatives as inhibitors of erk2 and uses thereof
MY141867A (en)	2002-06-20	2010-07-16	Vertex Pharma	Substituted pyrimidines useful as protein kinase inhibitors
WO2004005283A1 (en)	2002-07-09	2004-01-15	Vertex Pharmaceuticals Incorporated	Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
ATE339419T1 (de)	2002-08-02	2006-10-15	Vertex Pharma	Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
AU2003286711A1 (en)	2002-10-25	2004-05-13	Vertex Pharmaceuticals Incorporated	Indazolinone compositions useful as kinase inhibitors
JP2004224944A (ja) *	2003-01-24	2004-08-12	Kuraray Plast Co Ltd	高周波接着性に優れた熱可塑性樹脂組成物
US7579349B2 (en)	2003-10-17	2009-08-25	Astrazeneca Ab	4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
MY141220A (en) *	2003-11-17	2010-03-31	Astrazeneca Ab	Pyrazole derivatives as inhibitors of receptor tyrosine kinases
GB0402653D0 (en) *	2004-02-06	2004-03-10	Cyclacel Ltd	Compounds
JP2009502922A (ja)	2005-07-28	2009-01-29	バーテックスファーマシューティカルズインコーポレイテッド	カスパーゼ阻害剤プロドラッグ
AU2006279376B2 (en) *	2005-08-18	2011-04-14	Vertex Pharmaceuticals Incoporated	Pyrazine kinase inhibitors
WO2007023382A2 (en)	2005-08-25	2007-03-01	Pfizer Inc.	Pyrimidine amino pyrazole compounds, potent kinase inhibitors
NZ567241A (en) *	2005-09-30	2010-08-27	Miikana Therapeutics Inc	Substituted pyrazole compounds
EP1954277B1 (en)	2005-11-03	2017-01-18	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
CA2629781A1 (en)	2005-11-16	2007-05-24	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
NZ576750A (en) *	2006-11-02	2012-01-12	Vertex Pharma	Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
CA2673353A1 (en)	2006-12-19	2008-06-26	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as inhibitors of protein kinases
JP5283633B2 (ja) *	2006-12-29	2013-09-04	テイボテク・フアーマシユーチカルズ	Ｈｉｖ阻害性５，６−置換ピリミジン
ES2374335T3 (es)	2007-03-09	2012-02-15	Vertex Pharmaceuticals Incorporated	Aminopirimidinas útiles como inhibidores de proteína quinasas.
CA2679701A1 (en) *	2007-03-09	2008-09-18	Vertex Pharmaceuticals Incorporated	Aminopyridines useful as inhibitors of protein kinases
CN101663295B (zh) *	2007-03-09	2014-11-05	沃泰克斯药物股份有限公司	可用作蛋白激酶抑制剂的氨基嘧啶类化合物
AU2008228963A1 (en) *	2007-03-20	2008-09-25	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
EP2148931A2 (en)	2007-04-17	2010-02-03	Vertex Pharmaceuticals Incorporated	Drug discovery methods for aurora kinase inhibitors
EP2152696B1 (en)	2007-05-02	2014-09-24	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
JP5389785B2 (ja)	2007-05-02	2014-01-15	バーテックスファーマシューティカルズインコーポレイテッド	キナーゼ阻害剤として有用なチアゾールおよびピラゾール
WO2008137622A2 (en) *	2007-05-02	2008-11-13	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
CA2687966A1 (en) *	2007-05-24	2008-12-04	Vertex Pharmaceuticals Incorporated	Thiazoles and pyrazoles useful as kinase inhibitors
SG193156A1 (en)	2009-03-20	2013-09-30	Vertex Pharma	Process for making modulators of cystic fibrosis transmembrane conductance regulator

2006
- 2006-11-03 EP EP06836938.8A patent/EP1954277B1/en not_active Not-in-force
- 2006-11-03 AR ARP060104841A patent/AR056763A1/es not_active Application Discontinuation
- 2006-11-03 AU AU2006311797A patent/AU2006311797A1/en not_active Abandoned
- 2006-11-03 CA CA002627808A patent/CA2627808A1/en not_active Abandoned
- 2006-11-03 KR KR1020087013424A patent/KR20080067694A/ko not_active Application Discontinuation
- 2006-11-03 JP JP2008539070A patent/JP5249770B2/ja not_active Expired - Fee Related
- 2006-11-03 AU AU2006311830A patent/AU2006311830B2/en not_active Ceased
- 2006-11-03 NZ NZ594383A patent/NZ594383A/xx not_active IP Right Cessation
- 2006-11-03 CN CN2006800445831A patent/CN101316597B/zh not_active Expired - Fee Related
- 2006-11-03 NZ NZ594385A patent/NZ594385A/xx not_active IP Right Cessation
- 2006-11-03 MX MX2008005818A patent/MX2008005818A/es active IP Right Grant
- 2006-11-03 MX MX2008005814A patent/MX2008005814A/es active IP Right Grant
- 2006-11-03 BR BRPI0619706-0A patent/BRPI0619706A2/pt not_active IP Right Cessation
- 2006-11-03 US US11/592,113 patent/US7820685B2/en active Active
- 2006-11-03 EP EP06827465.3A patent/EP1951715B1/en not_active Not-in-force
- 2006-11-03 WO PCT/US2006/042994 patent/WO2007056164A2/en active Application Filing
- 2006-11-03 MX MX2008005717A patent/MX2008005717A/es active IP Right Grant
- 2006-11-03 AR ARP060104842A patent/AR057874A1/es not_active Application Discontinuation
- 2006-11-03 RU RU2008122046/04A patent/RU2423361C2/ru not_active IP Right Cessation
- 2006-11-03 BR BRPI0619704-3A patent/BRPI0619704A2/pt not_active IP Right Cessation
- 2006-11-03 CA CA002627857A patent/CA2627857A1/en not_active Abandoned
- 2006-11-03 US US11/592,114 patent/US7767672B2/en active Active
- 2006-11-03 US US11/592,119 patent/US7528142B2/en active Active
- 2006-11-03 KR KR1020087013281A patent/KR20080066069A/ko not_active Application Discontinuation
- 2006-11-03 ES ES06836890.1T patent/ES2533241T3/es active Active
- 2006-11-03 CN CN2006800444148A patent/CN101316843B/zh not_active Expired - Fee Related
- 2006-11-03 KR KR1020087013419A patent/KR20080067693A/ko not_active Application Discontinuation
- 2006-11-03 CN CN2012105636245A patent/CN103145702A/zh active Pending
- 2006-11-03 TW TW095140900A patent/TW200736250A/zh unknown
- 2006-11-03 NZ NZ606263A patent/NZ606263A/en not_active IP Right Cessation
- 2006-11-03 SG SG201008117-2A patent/SG166828A1/en unknown
- 2006-11-03 NZ NZ606259A patent/NZ606259A/en not_active IP Right Cessation
- 2006-11-03 RU RU2008122070/04A patent/RU2008122070A/ru not_active Application Discontinuation
- 2006-11-03 ES ES06827465T patent/ES2435081T3/es active Active
- 2006-11-03 EP EP06836890.1A patent/EP1948193B1/en not_active Not-in-force
- 2006-11-03 AU AU2006311831A patent/AU2006311831C1/en not_active Ceased
- 2006-11-03 RU RU2008122048/04A patent/RU2427578C2/ru not_active IP Right Cessation
- 2006-11-03 JP JP2008539091A patent/JP5328361B2/ja not_active Expired - Fee Related
- 2006-11-03 AR ARP060104843A patent/AR056764A1/es not_active Application Discontinuation
- 2006-11-03 CA CA002627830A patent/CA2627830A1/en not_active Abandoned
- 2006-11-03 TW TW095140878A patent/TW200734327A/zh unknown
- 2006-11-03 JP JP2008539071A patent/JP5249771B2/ja not_active Expired - Fee Related
- 2006-11-03 WO PCT/US2006/043096 patent/WO2007056221A2/en active Application Filing
- 2006-11-03 WO PCT/US2006/042993 patent/WO2007056163A2/en active Application Filing
- 2006-11-03 TW TW095140891A patent/TW200736249A/zh unknown
- 2006-11-03 BR BRPI0619708-6A patent/BRPI0619708A2/pt not_active IP Right Cessation
- 2006-11-03 SG SG201008116-4A patent/SG166827A1/en unknown
2008
- 2008-04-27 IL IL191043A patent/IL191043A0/en unknown
- 2008-04-27 IL IL191044A patent/IL191044A0/en unknown
- 2008-04-29 IL IL191140A patent/IL191140A0/en unknown
- 2008-05-30 NO NO20082508A patent/NO20082508L/no not_active Application Discontinuation
- 2008-05-30 NO NO20082514A patent/NO20082514L/no not_active Application Discontinuation
- 2008-05-30 NO NO20082517A patent/NO20082517L/no not_active Application Discontinuation
2009
- 2009-03-25 US US12/410,553 patent/US8129399B2/en active Active
2010
- 2010-06-08 US US12/796,297 patent/US8637511B2/en active Active
- 2010-09-30 US US12/894,465 patent/US8557833B2/en active Active
2011
- 2011-04-04 RU RU2011112948/15A patent/RU2011112948A/ru not_active Application Discontinuation
- 2011-05-05 RU RU2011118227/15A patent/RU2011118227A/ru not_active Application Discontinuation
- 2011-12-02 US US13/309,970 patent/US20120142660A1/en not_active Abandoned
2012
- 2012-12-12 JP JP2012271604A patent/JP2013049731A/ja active Pending
- 2012-12-19 JP JP2012276504A patent/JP2013075904A/ja active Pending

Also Published As

Publication number	Publication date
ES2435081T3 (es)	2013-12-18
CN101316597A (zh)	2008-12-03
BRPI0619706A2 (pt)	2011-10-11
EP1951715B1 (en)	2013-09-04
JP2009514887A (ja)	2009-04-09
AU2006311830A1 (en)	2007-05-18
AU2006311797A1 (en)	2007-05-18
EP1948193A2 (en)	2008-07-30
AR057874A1 (es)	2007-12-26
CN103145702A (zh)	2013-06-12
SG166828A1 (en)	2010-12-29
MX2008005818A (es)	2008-10-15
AU2006311831B2 (en)	2013-04-18
US7767672B2 (en)	2010-08-03
RU2423361C2 (ru)	2011-07-10
US20110020469A1 (en)	2011-01-27
US8557833B2 (en)	2013-10-15
CN101316843B (zh)	2013-01-02
AR056763A1 (es)	2007-10-24
NZ594383A (en)	2013-05-31
JP2013049731A (ja)	2013-03-14
JP2009514881A (ja)	2009-04-09
TW200736250A (en)	2007-10-01
IL191140A0 (en)	2008-12-29
CA2627808A1 (en)	2007-05-18
AU2006311831C1 (en)	2013-11-07
KR20080066069A (ko)	2008-07-15
JP2009514880A (ja)	2009-04-09
IL191043A0 (en)	2008-12-29
EP1948193A4 (en)	2011-11-09
US7820685B2 (en)	2010-10-26
TW200736249A (en)	2007-10-01
WO2007056163A2 (en)	2007-05-18
US20070249031A1 (en)	2007-10-25
NZ606263A (en)	2014-03-28
CA2627857A1 (en)	2007-05-18
EP1948193B1 (en)	2015-01-07
US20120142660A1 (en)	2012-06-07
WO2007056164A3 (en)	2007-12-13
BRPI0619708A2 (pt)	2011-10-11
JP5249771B2 (ja)	2013-07-31
US7528142B2 (en)	2009-05-05
ES2533241T3 (es)	2015-04-08
AR056764A1 (es)	2007-10-24
NZ606259A (en)	2014-06-27
JP2013075904A (ja)	2013-04-25
US20090181938A1 (en)	2009-07-16
MX2008005814A (es)	2008-10-15
CN101316843A (zh)	2008-12-03
KR20080067694A (ko)	2008-07-21
WO2007056164A2 (en)	2007-05-18
NO20082508L (no)	2008-07-31
RU2008122070A (ru)	2009-12-10
AU2006311831A1 (en)	2007-05-18
BRPI0619704A2 (pt)	2011-10-11
TW200734327A (en)	2007-09-16
CN101316597B (zh)	2013-04-17
AU2006311830B2 (en)	2013-03-14
JP5249770B2 (ja)	2013-07-31
NO20082517L (no)	2008-07-18
RU2011118227A (ru)	2012-11-10
CA2627830A1 (en)	2007-05-18
EP1954277A2 (en)	2008-08-13
RU2011112948A (ru)	2012-10-10
EP1954277A4 (en)	2011-11-09
US20080032963A1 (en)	2008-02-07
US20070259869A1 (en)	2007-11-08
WO2007056221A3 (en)	2007-12-06
US8637511B2 (en)	2014-01-28
EP1954277B1 (en)	2017-01-18
JP5328361B2 (ja)	2013-10-30
US8129399B2 (en)	2012-03-06
MX2008005717A (es)	2008-10-15
EP1951715A4 (en)	2011-11-09
NZ594385A (en)	2013-02-22
SG166827A1 (en)	2010-12-29
KR20080067693A (ko)	2008-07-21
EP1951715A2 (en)	2008-08-06
RU2008122046A (ru)	2009-12-10
US20100310675A1 (en)	2010-12-09
WO2007056163A3 (en)	2008-03-27
WO2007056221A2 (en)	2007-05-18
RU2427578C2 (ru)	2011-08-27
RU2008122048A (ru)	2009-12-10
IL191044A0 (en)	2008-12-29

Publication	Publication Date	Title
NO20082517L (no)	2008-07-18	Aminopyrimidiner anvendelige som kinaseinhibitorer
CY2021013I2 (el)	2021-12-31	Δι-αρυλ μετα-πυριμιδινο αναστολεις κινασων
DK1926722T3 (da)	2011-12-19	Substituerede benzimidazoler som kinaseinhibitorer
DK2261223T3 (da)	2013-09-23	Pyrimidinderivater anvendt som PI-3-kinasehæmmere
ATE512972T1 (de)	2011-07-15	Pyrrolopyrazole als wirksame kinaseinhibitoren
DK1943243T3 (da)	2011-03-07	Kinase-inhibitorer
DK1979356T3 (da)	2013-11-18	Carbonylaminopyrrolopyrazoler, kraftige kinaseinhibitorer
DK1959951T3 (da)	2010-03-01	Heteroaryl-substituerede piperidinderivater som L-CPT1-inhibitorer
DK1761505T3 (da)	2011-12-05	Pyrimidin-urinstof-derivater som kinaseinhibitorer
DK1881976T3 (da)	2013-02-04	Substituerede amidderivater som proteinkinaseinhibitorer
DK1846394T3 (da)	2012-01-16	Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
DK1711481T4 (da)	2013-08-26	Krystallinsk monohydrat som kinaseinhibitorer
DK2099447T3 (da)	2013-02-18	Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
DK2220070T3 (da)	2011-07-04	2-benzylpyridazinonderivater som Met-kinaseinhibitorer
NO20091423L (no)	2009-06-10	Pyrimidinderivater og deres anvendelse som kinaseinhibitorer
DK1910333T3 (da)	2013-08-19	Piperidinylsubstituerede isoquinolonderivater som RHO-kinaseinhibitorer
DK1789041T3 (da)	2008-09-08	Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1937671T3 (da)	2010-04-26	Benzimidazolthiophenforbindelser som PLK-inhibitorer
DK1797042T3 (da)	2009-03-02	Indozolonderivater som 11B-HSD1-inhibitorer
DK1763517T3 (da)	2011-06-06	Pyrimidinderivater som 11beta-HSD1-inhibitorer
ATE520664T1 (de)	2011-09-15	Tyrosinkinase-hemmer
ATE472532T1 (de)	2010-07-15	Oxindole als kinaseinhibitoren
DK1711177T3 (da)	2008-09-29	1H-thieno-2,3-c-pyrazolderivater, der er egnede som kinase-I-inhibitorer
DK1713805T3 (da)	2009-08-17	Kinaseinhibitorer
NO20084739L (no)	2009-01-06	Substituerte 3-cyanopyridiner som protein kinase inhibitorer

Legal Events

Date	Code	Title	Description
2013-06-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application